agranulocytosis/nausea

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 312 rezilta yo

Agranulocytosis associated with aprindine therapy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Aprindine hydrochloride is an antiarrhythmic drug now under investigation. The drug is most effective in prophylaxis of ventricular dysrhythmias. Previously recognized toxic effects include neurological side effects, nausea, vomiting, as well as a reported association with agranulocytosis. To our

[Efficacy observation of tigecycline in the treatment of 107 patients with infection due to granulocytopenia].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To observe the curative effect and side effect of tigecycline in the treatment of patients with infection caused by granulocytopenia. METHODS The clinical data of 107 patients who were treated with tigecycline for infection due to granulocytopenia were retrospectively reviewed. The

A case of agranulocytosis associated with severe acute hepatitis B.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 29-year-old male patient with acute hepatitis B developed agranulocytosis about 2 months after the clinical onset of the hepatitis. Bone marrow examination showed hypercellularity and maturation arrest of myeloid leukogenesis at the stage of metamyelocyte. Anti-neutrophil antibody was negative.

Reversible granulocytopenia in association with riluzole therapy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To report a case of severe neutropenia developing in association with riluzole 200 mg/d. METHODS A 63-year-old woman with amyotrophic lateral sclerosis (ALS) presented with nausea, anorexia, and fever two weeks following inadvertent dose escalation of riluzole from 100 to 200 mg/d.

A multi-center safety trial of the oral iron chelator deferiprone.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Deferiprone, also known as L1, is an orally active iron chelator that has been studied extensively in clinical trials. The sporadic occurrence of agranulocytosis in association with deferiprone and the highly variable frequency of other possible side effects such as arthralgia have created

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE This study was designed to assess the anti-tumor activity of topotecan (TPT) in patients with advanced non-small-cell lung cancer (NSCLC) previously untreated with chemotherapy. METHODS Patients with stage IIIB or IV NSCLC with measurable disease in nonradiated fields were eligible. Other

A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Mitoxantrone (Novantrone, N) is a new anthracenedione derivative with structural similarities to doxorubicin (Adriamycin, A). It has shown significant activity during phase I and II clinical trials in the treatment of advanced breast cancer. The present trial compares the CNF regimen to CAF. All

Ceftaroline - a cause for neutropenia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The US Food and Drug Administration approved ceftaroline in 2010 for the treatment of community-acquired pneumonia and skin and soft-tissue infections. The most common adverse reactions are diarrhoea, nausea and rash. To present the first case of neutropenia directly related to

[Evaluation of unexpected and toxic effects of omeprazole (Mopral) reported to the regional centers of pharmacovigilance during the first 22 postmarketing months].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Omeprazole has been marketed in France since 1989, for the healing of peptic ulcers, erosive reflux esophagitis and the Zollinger Ellison syndrome. It is a proton pump inhibitor which inhibits the acid secretion in the stomach. In the majority of the clinical trials, omeprazole has been found to be

Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To conduct a retrospective case analysis of the clinical efficacy and adverse effects of deferiprone in our population. METHODS All patients with transfusion-dependent thalassaemia at KK Hospital who have been on deferiprone were included in the study. Outcomes measured include the change

Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This report updates the combined experience of four centres involved in the long-term treatment of transfusional iron overload in 84 patients with the oral iron chelator deferiprone (L1) over 167 patient-years. The source of L1 was variable, including two university research laboratories and three

[Preliminary evaluation of adverse effects after administration of arabinoside cytosine (Ara-C) in high doses to children with acute myelogenous leukemia].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Five children with AML were treated with high-doses of Ara-C (2 g/m2) during consolidation. After 17 cycles the toxicity was evaluated. Granulocytopenia (< 0.5 x 10(9)/l) and thrombocytopenia (< 25 x 10(9)/l) were stated after 15/17 and 13/17 cycles respectively. The nadir of bone marrow suppression

Treatment of advanced gastric cancer with oral etoposide, leucovorin and tegafur: experience with an oral modification of the etoposide, leucovorin and 5-fluorouracil (ELF) regimen.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Recent data have suggested enhanced therapeutic activity with prolonged administration of both etoposide as well as fluoropyrimidines in the treatment of gastrointestinal malignancies. Based on this rationale, we investigated the clinical effectiveness and tolerance of an oral modification of the

Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We evaluated the effects of various schedules of peripheral blood stem cell (PBSC) reinfusion, granulocyte colony-stimulating factor (G-CSF) priming, and CD34+ enrichment on hematopoietic recovery in 88 patients with advanced breast cancer treated with high-dose chemotherapy, consisting of cisplatin

Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

It has been reported that 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11) and its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), have absorption characteristics of weakly basic drugs, suggesting that alkalization of the intestinal lumen might reduce

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye